Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$205.87 - $466.31
Previous CloseN/A
Volume78.96K
Average Volume (3M)1.21M
Market Cap
$60.07B
Enterprise Value$42.48B
Total Cash (Recent Filing)$2.86B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Oct 23, 2025EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding131,079,010
10 Day Avg. Volume1,277,658
30 Day Avg. Volume1,209,059
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue17.25
Enterprise Value/Gross Profit20.63
Enterprise Value/Ebitda-248.52
Forecast
1Y Price Target
$439.00Price Target Upside-6.11% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering27
Bulls Say, Bears Say
Bulls Say
EarningsALNY reported $492mm in Amvuttra sales, which was well above consensus expectations, elevating buyside expectations.
Financial PerformanceThe U.S. approval and launch of AMVUTTRA in ATTR-CM led to a sharp inflection in sales, prompting a $600M upward revision to full-year guidance.
Market ExpansionALNY received regulatory approval in Brazil, Europe, the UK, and Japan for its therapies, expanding its market reach.
Bears Say
Profit MarginsA 30% royalty payment to Sanofi affects Alnylam's margins, making Amvuttra less profitable.
Stock ValuationAlnylam's valuation is stretched, which still raises concerns despite positive market performance.
Alnylam Pharma News
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $205.87 and its highest was $466.31 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $60.07B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Oct 23, 2025 which is in 61 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Jul 31, 2025. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.544 by $0.034.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Overvalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 0.27.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 131,079,010 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.544. Following the earnings report the stock price went up 15.433%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$439.00 (-6.11% Downside)
$439.00 (-6.11% Downside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 162.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.47%
12-Months-Change
Fundamentals
Return on Equity
-257.82%
Trailing 12-Months
Asset Growth
13.88%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies based on RNA interference (RNAi). Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam is a leader in the RNAi therapeutics sector, aiming to treat a range of diseases by silencing specific genes. The company's core products include Onpattro (patisiran), which is approved for the treatment of hereditary transthyretin-mediated amyloidosis, and several other investigational therapies targeting various genetic disorders and conditions.
ALNY Company Deck
ALNY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Alnylam Q2 2025 highlighted strong commercial performance and successful product launches, particularly for AMVUTTRA in ATTR-CM, leading to an upgraded financial outlook. Despite some decreases in collaboration revenue and product sales margins, the overall sentiment remains highly positive due to the robust growth and positive future guidance.View all ALNY earnings summariesALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
$439.00
▼(-6.11% Downside)
Technical Analysis
Ownership Overview
0.40% Insiders
47.75% Mutual Funds
0.21% Other Institutional Investors
35.08% Public Companies and
Individual Investors